M&A Deal Summary |
|
|---|---|
| Date | 2013-06-28 |
| Target | Bard EP |
| Sector | Medical Products |
| Buyer(s) | Boston Scientific |
| Sellers(s) | C. R. Bard |
| Deal Type | Divestiture |
| Deal Value | 275M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1979 |
| Sector | Medical Products |
| Employees | 48,000 |
| Revenue | 16.7B USD (2024) |
Boston Scientific is a medical technology company that offers products and technologies used to diagnose and treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. Boston Scientific was founded in 1979 and is based in Marlborough, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 26 of 70 |
| Sector: Medical Products M&A | 17 of 53 |
| Type: Divestiture M&A Deals | 2 of 12 |
| State: Massachusetts M&A | 3 of 7 |
| Country: United States M&A | 22 of 55 |
| Year: 2013 M&A | 2 of 2 |
| Size (of disclosed) | 20 of 36 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-04-15 |
Anulex Technologies - FiXate Tissue Band
United States Anulex Technologies - FiXate Tissue Band is a novel suturing device that is designed to enable quick and simple placement of a suture to help secure a spinal cord stimulator (SCS) lead or pain pump catheter. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-05-06 |
IoGyn
Cupertino, California, United States IoGyn is a medical device start-up located in Cupertino, California focused on the development of safe and effective products for minimally-invasive gynecological surgery. IoGyn has developed and received U.S. Food and Drug Administration (FDA) clearance for the Symphion™ System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps. |
Buy | $65M |
| Category | Company |
|---|---|
| Founded | 1907 |
| Sector | Medical Products |
| Employees | 14,900 |
| Revenue | 3.7B USD (2016) |
C. R. Bard, Inc. is a multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. C. R. Bard was formed in 1907 and is based in Murray Hill, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2013 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-12-20 |
Lutonix
New Hope, Minnesota, United States Lutonix, Inc., delivers an optimal therapeutic dose of paclitaxel to stenosed peripheral and coronary vessels via a standard angioplasty balloon. |
Buy | $225M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-19 |
Medafor
Minneapolis, Minnesota, United States Medafor, Inc., is a developer and supplier of plant based hemostatic agents. Medafor develop and market its unique, patented hemostatic technology based on engineered biopolymeric microporous particles. |
Buy | $200M |
